Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
1986 3
1987 3
1989 3
1993 3
1994 3
1996 4
1997 1
1998 4
1999 4
2000 4
2001 7
2002 6
2003 10
2004 7
2005 8
2006 10
2007 7
2008 16
2009 7
2010 13
2011 11
2012 13
2013 18
2014 17
2015 9
2016 20
2017 23
2018 32
2019 22
2020 34
2021 25
2022 24
2023 36
2024 24
2025 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

402 results

Results by year

Filters applied: . Clear all
Page 1
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.
Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, Sunami K, Yoshida I, Yano H, Takahashi N, Okamoto A, Munemoto S, Sawazaki A, Suehiro Y, Fukuhara N, Wake A, Arai A, Masaki Y, Toyama K, Yokoyama A, Tsunemine H, Hasegawa Y, Matsumoto K, Yamada T, Nishimura Y, Tamaru S, Asano N, Miyawaki K, Izutsu K, Kinoshita T, Suzuki R, Ohshima K, Kato K, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: suehiro y. Cancer Sci. 2023 Jun;114(6):2689-2691. doi: 10.1111/cas.15784. Epub 2023 Mar 16. Cancer Sci. 2023. PMID: 36929591 Free PMC article. Clinical Trial. No abstract available.
Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Dinh M, Soong D, Noguchi H, Buchbjerg JK, Favaro E, Fukuhara N. Izutsu K, et al. Among authors: suehiro y. Cancer Sci. 2023 Dec;114(12):4643-4653. doi: 10.1111/cas.15996. Epub 2023 Nov 3. Cancer Sci. 2023. PMID: 37921363 Free PMC article.
A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma.
Yoshimitsu M, Choi I, Kusumoto S, Shimokawa M, Utsunomiya A, Suehiro Y, Hidaka T, Nosaka K, Sasaki H, Rai S, Tamura S, Owatari S, Koh KR, Nakamura D, Tokunaga M, Sekine M, Sakamoto Y, Inagaki H, Ishida T, Ishitsuka K. Yoshimitsu M, et al. Among authors: suehiro y. Blood. 2025 Sep 18;146(12):1440-1449. doi: 10.1182/blood.2024027902. Blood. 2025. PMID: 40373281 Clinical Trial.
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jażdżewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Kim WS, et al. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17. Nat Cancer. 2025. PMID: 40097657 Free PMC article. Clinical Trial.
Reply from the authors.
Kawaoka T, Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chayama K, Aikata H. Kawaoka T, et al. Among authors: suehiro y. Hepatol Res. 2020 Dec;50(12):1393. doi: 10.1111/hepr.13578. Hepatol Res. 2020. PMID: 33280200 No abstract available.
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Jafarinasabian P, Soong D, D'Angelo Månsson B, Takahashi A, Favaro E, Fukuhara N. Izutsu K, et al. Among authors: suehiro y. Int J Clin Oncol. 2025 Aug;30(8):1631-1640. doi: 10.1007/s10147-025-02788-0. Epub 2025 May 28. Int J Clin Oncol. 2025. PMID: 40434509 Free PMC article. Clinical Trial.
[HTLV-1-targeted immunotherapy].
Suehiro Y. Suehiro Y. Rinsho Ketsueki. 2016;57(10):2250-2258. doi: 10.11406/rinketsu.57.2250. Rinsho Ketsueki. 2016. PMID: 27795537 Japanese.
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial.
Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Conlon R, Takahashi A, D'Angelo Månsson B, Favaro E, Fukuhara N. Izutsu K, et al. Among authors: suehiro y. Leuk Lymphoma. 2025 Oct;66(10):1913-1921. doi: 10.1080/10428194.2025.2525983. Epub 2025 Jul 9. Leuk Lymphoma. 2025. PMID: 40632620 Free article. Clinical Trial.
Epstein-barr virus in gastric carcinoma.
Nishikawa J, Yoshiyama H, Iizasa H, Kanehiro Y, Nakamura M, Nishimura J, Saito M, Okamoto T, Sakai K, Suehiro Y, Yamasaki T, Oga A, Yanai H, Sakaida I. Nishikawa J, et al. Among authors: suehiro y. Cancers (Basel). 2014 Nov 7;6(4):2259-74. doi: 10.3390/cancers6042259. Cancers (Basel). 2014. PMID: 25386788 Free PMC article. Review.
Clinical Importance of Epstein⁻Barr Virus-Associated Gastric Cancer.
Nishikawa J, Iizasa H, Yoshiyama H, Shimokuri K, Kobayashi Y, Sasaki S, Nakamura M, Yanai H, Sakai K, Suehiro Y, Yamasaki T, Sakaida I. Nishikawa J, et al. Among authors: suehiro y. Cancers (Basel). 2018 May 29;10(6):167. doi: 10.3390/cancers10060167. Cancers (Basel). 2018. PMID: 29843478 Free PMC article. Review.
402 results